Shareholders who acted on the inside tip given by the rouge poster on PMCB's Facebook page were given a gift. IMO the recent shareholder call was a ruse to cover up a fatal flaw in the steps taken by PMCB over the past 15 years leading up to the IND for CIAB. As identified by the deleted internal post, the previously released human safety results were done over a decade ago, the data past its effective date, is therefore obsolete, and specifically did not enroll enough patients to compile enough credible data to make a reasonable determination that the enzymes being encapsulated will not biologically alter in vitro. In fact, the patient population in the early safety trial was 14, not near enough of a representative population for the FDA. This means the whole clinical trial process must be started over from the beginning. Unfortunately, if PMCB does not run out of cash and makes it to the IND, that is when you will find out you have to go back to start.

Don't take my word for it ... Read for yourself ...

Here are the FDA guidelines ...

https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073459.pdf

PMCB has missed it's golden opportunity to be the innovator. It is now far behind and chasing lower cost proven technology.



Beat to Market! Erytech is encapsulating therapeutic drug substances inside red blood cells. This eliminates PMCB's MCB issue, as patients bank their own blood. See for yourself the full data from its Phase 2b study evaluating it's technology for the treatment of metastatic pancreatic cancer. PMCB has no partner. PMCB is broke butt broke, and can't give away it's shelf offer. Erytech has TEVA backing, and was award granted 40mil + other grants. What Universities are PMCB partnered with? None = Red Flag. Longs think the Holy Grail is the submission of the IND. A Ham sandwich can submit an IND. Don't be fooled ... the Holy Grail is marketing approval, which comes after a successful 2b.
After THREE plus years of 2b clinicals, Erytech's 2b trials were successful, Marketing approval has been applied for, the technology patent is defendable, and the USA IPO is coming.

Do your DD, and drop the ZERO and get with a HERO!

Why is the new GMP compliant Cell Bank un-named? What was wrong with Astrinova, the one in Canada, and the others mentioned? The Italian Gov shut down the GMP complaints operation? Really? Has this been confirmed anywhere?

Classic Pump and Dilute ... Their only asset is people's belief in the technology. Yesterday the Technology died. Protect your capital!

Difference between ERYTECH and PMCB?

Look out below .... LOL! FY, Kenny!

Do yourself a favor and move your money to the MARKET LEADER in live cell encapsulation with patented technology that actually works, is past 2B trials, is still small cap @ 300 Mil CAP, is pending marketing approval, is backed by TEVA, and will IPO soon in the USA...

Drum roll, please ....

http://investors.erytech.com/phoenix.zhtml?c=254271&p=irol-newsArticle&ID=2299388

I am moving on .. I have dumped .. today is my day to bash, as is my right to do .. and then I move on to make money like I have done on ALL my other stocks in this raging bull market.

Here is a PMCB pumper/dumper giving the signal late October...

https://www.facebook.com/photo.php?fbid=158517261409208&set=a.111066766154258.1073741827.100017528049646&type=3&theater

After another 6-12 months of waiting with dead money, it will likely be the outcome that PMCB will have to go back to start. Their human safety study was only done with 14 patients. No way the FDA accepts that as an acceptable representation of the human population, especially with a different WCB and MCB. They already know this, as was posted from an insider in the know on their official Facebook feed.

I was long and willing to weather the swings, but have come to the conclusion (for my children's sake) I am a bag holder. Take out the dead. A fool has been parted with his money. MF'er!

If there is more interest in who the company is I will provide it.

The CC was arranged after that whole WTF facebook post where the unauthorized poster indicated the FDA would not accept PMCB's saftey patient DATA. It appears the CC was a pre-emptive coming clean before the whistle was blown on them.

We have been had. There is another that has discovered a better working live cell delivery system, and they are IPO'ing soon in the States.

It is deceptive to indicate trials will begin in Q1 2017. It will take 6 months (or longer) to grow the cell banks, and we are now in a "Q" waiting to start the process. The start date has not been indicated. Once grown the cell banks need to be tested for among other things sterility ... therefore add 6 weeks. Only after all has been completed can an IND be submitted.

This makes a Q1 target DOA, so why state it as fact?

It is deceptive to indicate that after January's conference call a patient a pivotal trial was designed for 40 patients. In that call it was identified that the FDA had indicated the trial needed to be plus 100 patients. The transcribed January conference has been removed from PMCB's web site. Why?

It is deceptive to issue positive press releases when the magnitude of the set back is understood. As recent as a few weeks ago a medical lab image was circulated inferring everything was "A OK" with the growing cells.

Tomorrow is going to be green because ...

PMCB just posted this message ...

"It's time to go purple! November is #PancreaticCancerAwarenessMonth. Join the Pancreatic Cancer Action Network: Demand Better and #WageHope...

and link .. https://www.pancan.org/

what was the reason the cells could not be grown with Austronova?

https://insiderfinancial.com/pharmacyte-biotech-inc-otcmktspmcb-is-at-a-turning-point

GTBP = Opportunity due to misinformation ...

What is up with GTBP?

They just now completed a RS (300:1) with OXIS. All Debt has been exchanged for equity, and they have stated they are funded for completing drug trials in progress. Currently they are OTCQB, but the RS and Debt free status opens the door to a NASDQ uplist, which they think will happen this year. The 1 year is down, and the stock looks to be coming off a bottom due to the RS.

Here is the opportunity ... OTC and others have the share count and MC wrong... Yahoo has the market cap @ 227 Mil. OTCmarkets has the CAP @ 150 Mill and OS @ 35 Mil.

However, according to official web site.. Post RS OS is now .5 Million and MC is 2.23 Mill.

WTF? The Investor Page of the official web site can't be wrong for legal reasons right? This is going to the moon yes / no? Guess we will see.

Links ...

Market Cap .... http://ir.stockpr.com/gtbiopharma/quote

Post Reverse Split Outstanding Shares @ 500,000 .... http://ir.gtbiopharma.com/press-releases/detail/117/gt-biopharma-inc-announces-reverse-stock-spilt-as-part-of

GTBP = Opportunity due to misinformation ...

What is up with GTBP?

They just now completed a RS (300:1) with OXIS. All Debt has been exchanged for equity, and they have stated they are funded for completing drug trials in progress. Currently they are OTCQB, but the RS and Debt free status opens the door to a NASDQ uplist, which they think will happen this year. The 1 year is down, and the stock looks to be coming off a bottom due to the RS.

Here is the opportunity ... OTC and others have the share count and MC wrong... Yahoo has the market cap @ 227 Mil. OTCmarkets has the CAP @ 150 Mill and OS @ 35 Mil.

However, according to official web site.. Post RS OS is now .5 Million and MC is 2.23 Mill.

WTF? The Investor Page of the official web site can't be wrong for legal reasons right? This is going to the moon yes / no? Guess we will see.

Links ...

Market Cap .... http://ir.stockpr.com/gtbiopharma/quote

Post Reverse Split Outstanding Shares @ 500,000 .... http://ir.gtbiopharma.com/press-releases/detail/117/gt-biopharma-inc-announces-reverse-stock-spilt-as-part-of

All clinical stage biotechs burn cash. No surprise! We should all be worried if PMCB were not raising a war chest. I do wish there was a more specific explanation of what the proceeds will be used for. Instead of "general working capital", how about "cost to fund pending clinical trials". Also, acquisitions are great for press releases, but what are our priorities here .. acquisitions, or trials? "Pivotal trial" is not even mentioned in the capital raise... why?

RE: Pump & Dilute scheme. I just have a real hard time believing that all the credentialed medical talent acquired in 2016 and 2017 are actually cohorts to management in a scheme to steal money from the hands that are feeding them. At the same time, Why are we still placing shares at deep discounts? WTF! The board better fix that or the community will never gain respect or confidence in the stock. How about we start flexing some gosh darn muscle around here!

Message to the new guy .... Where is our free money? Forget about giving shares away ... get us some Gosh Darn grants or contributions! This is cancer we are talking about... there are lots of foundations that would like to be connected and in some way responsible for "The cure". Get the free money, and you'll get premiums on your placements.

GTLA!

Re: 50% Sub-license ... I assume all revenue will be through sub-licensing. I mean, you don't think Doc Wags is personally going to implant all these cancer patients himself do you?

Good news is, 50% of 2 billion is still 1 billion. + PMCB gets 65% total, because they own 15% of Austranova.

This change of contract came about because both parties have dollar signs in their eyes.

An ongoing concern of mine has been how Austrinova gets funded. I know they got a first round at 40 mill, but that was years ago. Does anyone know, what are PMCB's rights now if Austrinova goes bankrupt again?

I predict a shake out at the open, followed by strong hands re-valuing this stock to HOD close into a Tuesday repeat. The turn higher will start with the eclipse .... GTLA!

Volume to pass 1 million shares Monday .... To the moon !

@AlanBrockstein .... With respect, and a true desire to learn from the best ... Does not SIGO like all emerging start-up companies, need to raise funds to advance operations. The 2 million $ that will be raised is going into the companies operating account, and they have stated they are in the process of signing contracts on an additional 100 to 200K SQFT facility. They need capital to sign those commitments. I would be more worried if they were not doing a capital raise in connection with aggressively expanding SQFT, and in light of the poor balance sheet. Also, the price of SIGO stock at the time of the registration was slightly above the new shares offer price... Something like .12 a share vs .10. No flag red flag there. There would be no way for principle holders to know that the stock would be where it is today, right? Last, how do we know that those .10 cent shares are not already issued and trading today, until we see the next 10Q?

Please Alan, what are your thoughts on this .... Were does this logic go wrong?

AS is now 100,000,000 per RS and recent clarification in 8K.

Expiration of CIAB patent.... It is not relevant weather or not patent for CIAB has expired, as PMCB has filed for PP on the entire therapy, not just CIAB. PMCB is one step ahead, as they executed this just prior to the CIAB expiration, and the new PP is an improvement over the original patent, and therefore patentable.

https://globenewswire.com/news-release/2017/03/22/943094/0/en/PharmaCyte-Biotech-Strengthens-Protection-of-Cancer-Therapy-with-Patent-Filing.html

PMCB purchased the rights to "CapCell" renamed "Cell in a Box" in 2013. The rights to use the technology do not expire.

https://www.sec.gov/Archives/edgar/data/1157075/000101968714002153/filename1.htm

Some speculation ... the last two talent additions to PMCB have extensive backgrounds in transplant surgery... in link below, see section titled " what are the obstacles to pancreatic islet allo-transplantation". Possibly PMCB has figured out a way to increase the amount of islets that survive transplantation, or have come up with a product that eliminates the need for pancreas islets altogether (RE: Diabetes)

https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments/pancreatic-islet-transplantation

It would seem logical that China would take interest in CIAB... after all, Cell in a box's production lab is located in Singapore / Bangkok. Austrianova did not locate there in a vac.... why not NA or Europe?

However, wild speculation seems a little desperate sitting at .05/.06, so if there is a link, or a scientist working with the tech, please put the link up.

About today's press release ... new link.

I liked the release, so I added to my bag holder position. I liked the price and the idea that PMCB is going to be accepting an award, and formally presenting in a public forum (Audience of scientists, doctors, investors. and reporters). Anything can happen here, so they must be confident to present to their peers in public. This will be unlike KW's "submit your questions" and pre-recorded investor web go-to-meeting, or their invite only closed door discussion with the mostly unidentified "experts" at the most recent convention. This one should be charged with speculative onlookers.... and I hope they hit the ball hard enough to get some new money flowing in.

Anyway ... Here is the list of attendees, and it appears impressive..

http://convention.bio.org/uploadedFiles/2012/Explore_the_Program/2017_PresentingCompanies.xlsx

Where Pharmacyte? .... just look two below Phizer!

GLTA :)

Volume has been much better (vs Feb & March) and the limit order I set up two weeks ago (.085 ) hit yesterday... shoot ! Never thought the price would get that low!

I am "Dollar'ed down" now, have too much skin in this for comfort, and these F'ers better start leaking some concrete plans .... I hope not to be trapped until 2018 ... lol, gulp!

GTLA!

Thanks for correcting me ... Big difference. That is why I put what I am thinking out there... So it can be corrected, or validated. I am not too worried about dilution based on the limits placed on Chardan by PMCB. We have worked with them before, and they are not fly by night.

Here is what is up ....

http://www.sharemarketschool.com/spot-stock-market%C2%A0trends-using-price-and-volume/

We need volume consistently above 3.5 mill to reverse.

I'm done for the day... GL all!

The 50,000,000 authorized shares Charlatan has been retained to sell is a 6.5% dillition.

Again, big F'ing deal in the scheme of things! If this is what we all imagine, we are looking at 1000+ % before revenue!

If correct (+\-).... that represents @ 1.5% dilution.

F'ing negligible in the scheme of things!